Literature DB >> 2931345

Single dose ciprofloxacin for treating gonococcal infections in men.

P S Loo, G L Ridgway, J D Oriel.   

Abstract

A single oral dose of ciprofloxacin 500 mg was used to treat five men with gonococcal urethritis and five men with gonococcal proctitis, and all were cured. In a subsequent study the dose of ciprofloxacin was reduced to 250 mg, and 54 men with 57 gonococcal infections (47 urethral, seven rectal, and three pharyngeal) were treated; of the isolates of Neisseria gonorrhoeae, four were penicillinase producing strains. All the patients were cured of gonococcal infection. Urethral specimens from nine of the men with gonococcal urethritis yielded Chlamydia trachomatis before treatment. These organisms were isolated again from all these patients seven days after treatment, and from a further seven men who had been chlamydia negative before treatment. It is concluded that a single oral dose of ciprofloxacin is an effective treatment for uncomplicated gonorrhoea, but is ineffective against C trachomatis. Of the 54 men given 250 mg ciprofloxacin, six (11%) showed minor abnormalities of liver function tests after treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2931345      PMCID: PMC1011843          DOI: 10.1136/sti.61.5.302

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  17 in total

1.  Diagnosis of gonorrhoea by culture on a selective medium containing vancomycin, colistin, nystatin and trimethoprim (VCNT). A comparison with Gram-staining and immunofluorescence.

Authors:  I Phillips; D Humphrey; A Middleton; C S Nicol
Journal:  Br J Vener Dis       Date:  1972-08

2.  Spectinomycin-resistant penicillinase-producing Neisseria gonorrhoeae.

Authors:  W A Ashford; D W Potts; H J Adams; J C English; S R Johnson; J W Biddle; C Thornsberry; H W Jaffe
Journal:  Lancet       Date:  1981-11-07       Impact factor: 79.321

3.  Cefotaxime for spectinomycin resistant Neisseria gonorrhoeae.

Authors:  A J Boakes; J Barrow; S J Eykyn; I Phillips
Journal:  Lancet       Date:  1981-07-11       Impact factor: 79.321

4.  Penicillinase-producing Neisseria gonorrhoeae--a retrospective.

Authors:  W M McCormack
Journal:  N Engl J Med       Date:  1982-08-12       Impact factor: 91.245

5.  Penicillinase-producing Neisseria gonorrhoeae in Great Britain, 1977-81: alarming increase in incidence and recent development of endemic transmission.

Authors:  J A McCutchan; M W Adler; J R Berrie
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-31

6.  Single-dose minocycline in the treatment of gonococcal urethritis. Clinical efficacy in relation to bacterial resistance and its effects on associated Chlamydia trachomatis infections.

Authors:  P M Waterworth; J D Oriel; G L Ridgway; S Subramanian
Journal:  Br J Vener Dis       Date:  1979-10

7.  Antimicrobial resistance of Neisseria gonorrhoea in Bangkok: is single-drug treatment passé.

Authors:  S Brown; T Warnnissorn; J Biddle; K Panikabutra; A Traisupa
Journal:  Lancet       Date:  1982-12-18       Impact factor: 79.321

8.  Penicillin sensitivity of gonococci. An evaluation of monitoring as an index of epidemiological control.

Authors:  D H Jackson; A E Jephcott
Journal:  Br J Vener Dis       Date:  1976-08

9.  The lack of effect of ampicillin plus probenecid given for genital infections with Neisseria gonorrhoeae on associated infections with Chlamydia trachomatis.

Authors:  J D Oriel; G L Ridgway; P Reeve; D C Beckingham; J Owen
Journal:  J Infect Dis       Date:  1976-05       Impact factor: 5.226

10.  Treatment of uncomplicated gonorrhea with rosoxacin.

Authors:  H H Handsfield; F N Judson; K K Holmes
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

View more
  25 in total

1.  Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.

Authors:  M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

2.  Ciprofloxacin resistant Neisseria gonorrhoeae in the UK.

Authors:  A Turner; A E Jephcott; T C Haji; P C Gupta
Journal:  Genitourin Med       Date:  1990-02

Review 3.  Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

4.  In vitro activity of the two new 4-quinolones A56619 and A56620 against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum and Gardnerella vaginalis.

Authors:  K H Tjiam; J H Wagenvoort; B van Klingeren; P Piot; E Stolz; M F Michel
Journal:  Eur J Clin Microbiol       Date:  1986-10       Impact factor: 3.267

Review 5.  Quinolone antibacterial agents for the treatment of genitourinary tract infections.

Authors:  T J Babinchak; R J Fass
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

6.  Single dose ciprofloxacin to treat women with gonorrhoea.

Authors:  K Shanmugaratnam; M S Sprott; R S Pattman; A M Kearns; P G Watson
Journal:  Genitourin Med       Date:  1989-04

7.  In vitro activity and mode of action of fluoroquinolones.

Authors:  L Verbist
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

8.  Treating uncomplicated gonococcal infection with 250 mg or 100 mg ciprofloxacin in a single oral dose.

Authors:  D Avonts; L Fransen; J Vielfont; A Stevens; K Hendrickx; P Piot
Journal:  Genitourin Med       Date:  1988-04

9.  High prevalence of Neisseria gonorrhoeae strains with reduced susceptibility to fluoroquinolones in Japan.

Authors:  M Tanaka; J Kumazawa; T Matsumoto; I Kobayashi
Journal:  Genitourin Med       Date:  1994-04

10.  Comparison of ciprofloxacin and ceftriaxone as single-dose therapy for uncomplicated gonorrhea in women.

Authors:  E W Hook; R B Jones; D H Martin; G A Bolan; T F Mroczkowski; T M Neumann; J J Haag; R Echols
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.